GlucoTrack, Inc.
GlucoTrack, Inc. IGAP Peers
See (IGAP) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Instruments & Supplies Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| IGAP | $3.24 | +2.86% | 50.2M | -10.52 | -$0.31 | N/A |
| ISRG | $551.76 | -0.28% | 197.8B | 80.55 | $6.85 | N/A |
| BDXA | $59.24 | -2.24% | 49.1B | 21.44 | $2.76 | +2.33% |
| BDX | $170.70 | +0.77% | 48.9B | 33.08 | $5.16 | +2.33% |
| ALC | $85.42 | +0.29% | 42.2B | 37.96 | $2.25 | +0.39% |
| RMD | $247.11 | +1.26% | 36.2B | 27.73 | $8.91 | +0.86% |
| BAX | $30.09 | +1.84% | 15.4B | -57.87 | -$0.52 | +2.67% |
| WST | $210.69 | +0.62% | 15.1B | 33.08 | $6.37 | +0.39% |
| HOLX | $63.04 | +1.66% | 14B | 26.49 | $2.38 | N/A |
| BDXB | $48.16 | +1.39% | 13.7B | 7.60 | $6.33 | +2.33% |
Stock Comparison
IGAP vs ISRG Comparison
IGAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IGAP stands at 50.2M. In comparison, ISRG has a market cap of 197.8B. Regarding current trading prices, IGAP is priced at $3.24, while ISRG trades at $551.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IGAP currently has a P/E ratio of -10.52, whereas ISRG's P/E ratio is 80.55. In terms of profitability, IGAP's ROE is +3.93%, compared to ISRG's ROE of +0.16%. Regarding short-term risk, IGAP is more volatile compared to ISRG. This indicates potentially higher risk in terms of short-term price fluctuations for IGAP.
IGAP vs BDXA Comparison
IGAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IGAP stands at 50.2M. In comparison, BDXA has a market cap of 49.1B. Regarding current trading prices, IGAP is priced at $3.24, while BDXA trades at $59.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IGAP currently has a P/E ratio of -10.52, whereas BDXA's P/E ratio is 21.44. In terms of profitability, IGAP's ROE is +3.93%, compared to BDXA's ROE of +0.06%. Regarding short-term risk, IGAP is less volatile compared to BDXA. This indicates potentially lower risk in terms of short-term price fluctuations for IGAP.
IGAP vs BDX Comparison
IGAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IGAP stands at 50.2M. In comparison, BDX has a market cap of 48.9B. Regarding current trading prices, IGAP is priced at $3.24, while BDX trades at $170.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IGAP currently has a P/E ratio of -10.52, whereas BDX's P/E ratio is 33.08. In terms of profitability, IGAP's ROE is +3.93%, compared to BDX's ROE of +0.06%. Regarding short-term risk, IGAP is more volatile compared to BDX. This indicates potentially higher risk in terms of short-term price fluctuations for IGAP.
IGAP vs ALC Comparison
IGAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IGAP stands at 50.2M. In comparison, ALC has a market cap of 42.2B. Regarding current trading prices, IGAP is priced at $3.24, while ALC trades at $85.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IGAP currently has a P/E ratio of -10.52, whereas ALC's P/E ratio is 37.96. In terms of profitability, IGAP's ROE is +3.93%, compared to ALC's ROE of +0.07%. Regarding short-term risk, IGAP is more volatile compared to ALC. This indicates potentially higher risk in terms of short-term price fluctuations for IGAP.
IGAP vs RMD Comparison
IGAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IGAP stands at 50.2M. In comparison, RMD has a market cap of 36.2B. Regarding current trading prices, IGAP is priced at $3.24, while RMD trades at $247.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IGAP currently has a P/E ratio of -10.52, whereas RMD's P/E ratio is 27.73. In terms of profitability, IGAP's ROE is +3.93%, compared to RMD's ROE of +0.25%. Regarding short-term risk, IGAP is more volatile compared to RMD. This indicates potentially higher risk in terms of short-term price fluctuations for IGAP.
IGAP vs BAX Comparison
IGAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IGAP stands at 50.2M. In comparison, BAX has a market cap of 15.4B. Regarding current trading prices, IGAP is priced at $3.24, while BAX trades at $30.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IGAP currently has a P/E ratio of -10.52, whereas BAX's P/E ratio is -57.87. In terms of profitability, IGAP's ROE is +3.93%, compared to BAX's ROE of -0.08%. Regarding short-term risk, IGAP is less volatile compared to BAX. This indicates potentially lower risk in terms of short-term price fluctuations for IGAP.
IGAP vs WST Comparison
IGAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IGAP stands at 50.2M. In comparison, WST has a market cap of 15.1B. Regarding current trading prices, IGAP is priced at $3.24, while WST trades at $210.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IGAP currently has a P/E ratio of -10.52, whereas WST's P/E ratio is 33.08. In terms of profitability, IGAP's ROE is +3.93%, compared to WST's ROE of +0.17%. Regarding short-term risk, IGAP is less volatile compared to WST. This indicates potentially lower risk in terms of short-term price fluctuations for IGAP.
IGAP vs HOLX Comparison
IGAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IGAP stands at 50.2M. In comparison, HOLX has a market cap of 14B. Regarding current trading prices, IGAP is priced at $3.24, while HOLX trades at $63.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IGAP currently has a P/E ratio of -10.52, whereas HOLX's P/E ratio is 26.49. In terms of profitability, IGAP's ROE is +3.93%, compared to HOLX's ROE of +0.11%. Regarding short-term risk, IGAP is less volatile compared to HOLX. This indicates potentially lower risk in terms of short-term price fluctuations for IGAP.
IGAP vs BDXB Comparison
IGAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IGAP stands at 50.2M. In comparison, BDXB has a market cap of 13.7B. Regarding current trading prices, IGAP is priced at $3.24, while BDXB trades at $48.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IGAP currently has a P/E ratio of -10.52, whereas BDXB's P/E ratio is 7.60. In terms of profitability, IGAP's ROE is +3.93%, compared to BDXB's ROE of +0.06%. Regarding short-term risk, IGAP is less volatile compared to BDXB. This indicates potentially lower risk in terms of short-term price fluctuations for IGAP.
IGAP vs COO Comparison
IGAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IGAP stands at 50.2M. In comparison, COO has a market cap of 13.4B. Regarding current trading prices, IGAP is priced at $3.24, while COO trades at $66.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IGAP currently has a P/E ratio of -10.52, whereas COO's P/E ratio is 32.33. In terms of profitability, IGAP's ROE is +3.93%, compared to COO's ROE of +0.05%. Regarding short-term risk, IGAP is less volatile compared to COO. This indicates potentially lower risk in terms of short-term price fluctuations for IGAP.
IGAP vs ATR Comparison
IGAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IGAP stands at 50.2M. In comparison, ATR has a market cap of 10.3B. Regarding current trading prices, IGAP is priced at $3.24, while ATR trades at $156.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IGAP currently has a P/E ratio of -10.52, whereas ATR's P/E ratio is 28.61. In terms of profitability, IGAP's ROE is +3.93%, compared to ATR's ROE of +0.15%. Regarding short-term risk, IGAP is more volatile compared to ATR. This indicates potentially higher risk in terms of short-term price fluctuations for IGAP.
IGAP vs MASI Comparison
IGAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IGAP stands at 50.2M. In comparison, MASI has a market cap of 8.9B. Regarding current trading prices, IGAP is priced at $3.24, while MASI trades at $163.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IGAP currently has a P/E ratio of -10.52, whereas MASI's P/E ratio is -30.00. In terms of profitability, IGAP's ROE is +3.93%, compared to MASI's ROE of -0.41%. Regarding short-term risk, IGAP is less volatile compared to MASI. This indicates potentially lower risk in terms of short-term price fluctuations for IGAP.
IGAP vs RGEN Comparison
IGAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IGAP stands at 50.2M. In comparison, RGEN has a market cap of 7B. Regarding current trading prices, IGAP is priced at $3.24, while RGEN trades at $124.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IGAP currently has a P/E ratio of -10.52, whereas RGEN's P/E ratio is -289.28. In terms of profitability, IGAP's ROE is +3.93%, compared to RGEN's ROE of -0.01%. Regarding short-term risk, IGAP is less volatile compared to RGEN. This indicates potentially lower risk in terms of short-term price fluctuations for IGAP.
IGAP vs STVN Comparison
IGAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IGAP stands at 50.2M. In comparison, STVN has a market cap of 5.9B. Regarding current trading prices, IGAP is priced at $3.24, while STVN trades at $21.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IGAP currently has a P/E ratio of -10.52, whereas STVN's P/E ratio is 41.83. In terms of profitability, IGAP's ROE is +3.93%, compared to STVN's ROE of +0.09%. Regarding short-term risk, IGAP is less volatile compared to STVN. This indicates potentially lower risk in terms of short-term price fluctuations for IGAP.
IGAP vs MMSI Comparison
IGAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IGAP stands at 50.2M. In comparison, MMSI has a market cap of 5.6B. Regarding current trading prices, IGAP is priced at $3.24, while MMSI trades at $94.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IGAP currently has a P/E ratio of -10.52, whereas MMSI's P/E ratio is 46.39. In terms of profitability, IGAP's ROE is +3.93%, compared to MMSI's ROE of +0.09%. Regarding short-term risk, IGAP is more volatile compared to MMSI. This indicates potentially higher risk in terms of short-term price fluctuations for IGAP.
IGAP vs TFX Comparison
IGAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IGAP stands at 50.2M. In comparison, TFX has a market cap of 5.4B. Regarding current trading prices, IGAP is priced at $3.24, while TFX trades at $121.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IGAP currently has a P/E ratio of -10.52, whereas TFX's P/E ratio is 37.58. In terms of profitability, IGAP's ROE is +3.93%, compared to TFX's ROE of +0.03%. Regarding short-term risk, IGAP is less volatile compared to TFX. This indicates potentially lower risk in terms of short-term price fluctuations for IGAP.
IGAP vs BLCO Comparison
IGAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IGAP stands at 50.2M. In comparison, BLCO has a market cap of 4.1B. Regarding current trading prices, IGAP is priced at $3.24, while BLCO trades at $11.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IGAP currently has a P/E ratio of -10.52, whereas BLCO's P/E ratio is -11.25. In terms of profitability, IGAP's ROE is +3.93%, compared to BLCO's ROE of -0.08%. Regarding short-term risk, IGAP is less volatile compared to BLCO. This indicates potentially lower risk in terms of short-term price fluctuations for IGAP.
IGAP vs HAE Comparison
IGAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IGAP stands at 50.2M. In comparison, HAE has a market cap of 3.3B. Regarding current trading prices, IGAP is priced at $3.24, while HAE trades at $69.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IGAP currently has a P/E ratio of -10.52, whereas HAE's P/E ratio is 21.04. In terms of profitability, IGAP's ROE is +3.93%, compared to HAE's ROE of +0.18%. Regarding short-term risk, IGAP is less volatile compared to HAE. This indicates potentially lower risk in terms of short-term price fluctuations for IGAP.
IGAP vs ICUI Comparison
IGAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IGAP stands at 50.2M. In comparison, ICUI has a market cap of 3.2B. Regarding current trading prices, IGAP is priced at $3.24, while ICUI trades at $130.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IGAP currently has a P/E ratio of -10.52, whereas ICUI's P/E ratio is -34.09. In terms of profitability, IGAP's ROE is +3.93%, compared to ICUI's ROE of -0.05%. Regarding short-term risk, IGAP is less volatile compared to ICUI. This indicates potentially lower risk in terms of short-term price fluctuations for IGAP.
IGAP vs XRAY Comparison
IGAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IGAP stands at 50.2M. In comparison, XRAY has a market cap of 3.2B. Regarding current trading prices, IGAP is priced at $3.24, while XRAY trades at $15.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IGAP currently has a P/E ratio of -10.52, whereas XRAY's P/E ratio is -3.55. In terms of profitability, IGAP's ROE is +3.93%, compared to XRAY's ROE of -0.38%. Regarding short-term risk, IGAP is less volatile compared to XRAY. This indicates potentially lower risk in terms of short-term price fluctuations for IGAP.
IGAP vs WRBY Comparison
IGAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IGAP stands at 50.2M. In comparison, WRBY has a market cap of 2.5B. Regarding current trading prices, IGAP is priced at $3.24, while WRBY trades at $20.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IGAP currently has a P/E ratio of -10.52, whereas WRBY's P/E ratio is -173.25. In terms of profitability, IGAP's ROE is +3.93%, compared to WRBY's ROE of -0.04%. Regarding short-term risk, IGAP is less volatile compared to WRBY. This indicates potentially lower risk in terms of short-term price fluctuations for IGAP.
IGAP vs QDEL Comparison
IGAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IGAP stands at 50.2M. In comparison, QDEL has a market cap of 2B. Regarding current trading prices, IGAP is priced at $3.24, while QDEL trades at $30.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IGAP currently has a P/E ratio of -10.52, whereas QDEL's P/E ratio is -5.79. In terms of profitability, IGAP's ROE is +3.93%, compared to QDEL's ROE of -0.11%. Regarding short-term risk, IGAP is less volatile compared to QDEL. This indicates potentially lower risk in terms of short-term price fluctuations for IGAP.
IGAP vs NVCR Comparison
IGAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IGAP stands at 50.2M. In comparison, NVCR has a market cap of 1.9B. Regarding current trading prices, IGAP is priced at $3.24, while NVCR trades at $17.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IGAP currently has a P/E ratio of -10.52, whereas NVCR's P/E ratio is -11.30. In terms of profitability, IGAP's ROE is +3.93%, compared to NVCR's ROE of -0.45%. Regarding short-term risk, IGAP is less volatile compared to NVCR. This indicates potentially lower risk in terms of short-term price fluctuations for IGAP.
IGAP vs LMAT Comparison
IGAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IGAP stands at 50.2M. In comparison, LMAT has a market cap of 1.9B. Regarding current trading prices, IGAP is priced at $3.24, while LMAT trades at $82.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IGAP currently has a P/E ratio of -10.52, whereas LMAT's P/E ratio is 42.07. In terms of profitability, IGAP's ROE is +3.93%, compared to LMAT's ROE of +0.14%. Regarding short-term risk, IGAP is less volatile compared to LMAT. This indicates potentially lower risk in terms of short-term price fluctuations for IGAP.
IGAP vs ATRC Comparison
IGAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IGAP stands at 50.2M. In comparison, ATRC has a market cap of 1.7B. Regarding current trading prices, IGAP is priced at $3.24, while ATRC trades at $34.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IGAP currently has a P/E ratio of -10.52, whereas ATRC's P/E ratio is -42.88. In terms of profitability, IGAP's ROE is +3.93%, compared to ATRC's ROE of -0.08%. Regarding short-term risk, IGAP is less volatile compared to ATRC. This indicates potentially lower risk in terms of short-term price fluctuations for IGAP.
IGAP vs AZTA Comparison
IGAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IGAP stands at 50.2M. In comparison, AZTA has a market cap of 1.3B. Regarding current trading prices, IGAP is priced at $3.24, while AZTA trades at $28.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IGAP currently has a P/E ratio of -10.52, whereas AZTA's P/E ratio is -8.67. In terms of profitability, IGAP's ROE is +3.93%, compared to AZTA's ROE of -0.04%. Regarding short-term risk, IGAP is less volatile compared to AZTA. This indicates potentially lower risk in terms of short-term price fluctuations for IGAP.
IGAP vs PLSE Comparison
IGAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IGAP stands at 50.2M. In comparison, PLSE has a market cap of 1.2B. Regarding current trading prices, IGAP is priced at $3.24, while PLSE trades at $17.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IGAP currently has a P/E ratio of -10.52, whereas PLSE's P/E ratio is -17.81. In terms of profitability, IGAP's ROE is +3.93%, compared to PLSE's ROE of -0.71%. Regarding short-term risk, IGAP is less volatile compared to PLSE. This indicates potentially lower risk in terms of short-term price fluctuations for IGAP.
IGAP vs BLFS Comparison
IGAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IGAP stands at 50.2M. In comparison, BLFS has a market cap of 1B. Regarding current trading prices, IGAP is priced at $3.24, while BLFS trades at $21.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IGAP currently has a P/E ratio of -10.52, whereas BLFS's P/E ratio is -112.45. In terms of profitability, IGAP's ROE is +3.93%, compared to BLFS's ROE of -0.03%. Regarding short-term risk, IGAP is less volatile compared to BLFS. This indicates potentially lower risk in terms of short-term price fluctuations for IGAP.
IGAP vs KMTS Comparison
IGAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IGAP stands at 50.2M. In comparison, KMTS has a market cap of 1B. Regarding current trading prices, IGAP is priced at $3.24, while KMTS trades at $19.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IGAP currently has a P/E ratio of -10.52, whereas KMTS's P/E ratio is -10.15. In terms of profitability, IGAP's ROE is +3.93%, compared to KMTS's ROE of +0.27%. Regarding short-term risk, IGAP is less volatile compared to KMTS. This indicates potentially lower risk in terms of short-term price fluctuations for IGAP.
IGAP vs STAA Comparison
IGAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IGAP stands at 50.2M. In comparison, STAA has a market cap of 848.9M. Regarding current trading prices, IGAP is priced at $3.24, while STAA trades at $17.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IGAP currently has a P/E ratio of -10.52, whereas STAA's P/E ratio is -11.90. In terms of profitability, IGAP's ROE is +3.93%, compared to STAA's ROE of -0.18%. Regarding short-term risk, IGAP is less volatile compared to STAA. This indicates potentially lower risk in terms of short-term price fluctuations for IGAP.
IGAP vs ATRI Comparison
IGAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IGAP stands at 50.2M. In comparison, ATRI has a market cap of 809.4M. Regarding current trading prices, IGAP is priced at $3.24, while ATRI trades at $459.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IGAP currently has a P/E ratio of -10.52, whereas ATRI's P/E ratio is 64.50. In terms of profitability, IGAP's ROE is +3.93%, compared to ATRI's ROE of +0.04%. Regarding short-term risk, IGAP is more volatile compared to ATRI. This indicates potentially higher risk in terms of short-term price fluctuations for IGAP.
IGAP vs ANGO Comparison
IGAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IGAP stands at 50.2M. In comparison, ANGO has a market cap of 445.1M. Regarding current trading prices, IGAP is priced at $3.24, while ANGO trades at $10.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IGAP currently has a P/E ratio of -10.52, whereas ANGO's P/E ratio is -10.85. In terms of profitability, IGAP's ROE is +3.93%, compared to ANGO's ROE of -0.21%. Regarding short-term risk, IGAP is less volatile compared to ANGO. This indicates potentially lower risk in terms of short-term price fluctuations for IGAP.
IGAP vs NNNN Comparison
IGAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IGAP stands at 50.2M. In comparison, NNNN has a market cap of 359M. Regarding current trading prices, IGAP is priced at $3.24, while NNNN trades at $8.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IGAP currently has a P/E ratio of -10.52, whereas NNNN's P/E ratio is 163.60. In terms of profitability, IGAP's ROE is +3.93%, compared to NNNN's ROE of +0.14%. Regarding short-term risk, IGAP is less volatile compared to NNNN. This indicates potentially lower risk in terms of short-term price fluctuations for IGAP.
IGAP vs NYXH Comparison
IGAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IGAP stands at 50.2M. In comparison, NYXH has a market cap of 292.9M. Regarding current trading prices, IGAP is priced at $3.24, while NYXH trades at $7.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IGAP currently has a P/E ratio of -10.52, whereas NYXH's P/E ratio is -3.45. In terms of profitability, IGAP's ROE is +3.93%, compared to NYXH's ROE of -0.56%. Regarding short-term risk, IGAP is less volatile compared to NYXH. This indicates potentially lower risk in terms of short-term price fluctuations for IGAP.
IGAP vs SMTI Comparison
IGAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IGAP stands at 50.2M. In comparison, SMTI has a market cap of 256.6M. Regarding current trading prices, IGAP is priced at $3.24, while SMTI trades at $28.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IGAP currently has a P/E ratio of -10.52, whereas SMTI's P/E ratio is -21.54. In terms of profitability, IGAP's ROE is +3.93%, compared to SMTI's ROE of -0.29%. Regarding short-term risk, IGAP is less volatile compared to SMTI. This indicates potentially lower risk in terms of short-term price fluctuations for IGAP.
IGAP vs OSUR Comparison
IGAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IGAP stands at 50.2M. In comparison, OSUR has a market cap of 221.4M. Regarding current trading prices, IGAP is priced at $3.24, while OSUR trades at $2.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IGAP currently has a P/E ratio of -10.52, whereas OSUR's P/E ratio is -7.05. In terms of profitability, IGAP's ROE is +3.93%, compared to OSUR's ROE of -0.08%. Regarding short-term risk, IGAP is less volatile compared to OSUR. This indicates potentially lower risk in terms of short-term price fluctuations for IGAP.
IGAP vs STXS Comparison
IGAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IGAP stands at 50.2M. In comparison, STXS has a market cap of 196.9M. Regarding current trading prices, IGAP is priced at $3.24, while STXS trades at $2.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IGAP currently has a P/E ratio of -10.52, whereas STXS's P/E ratio is -7.39. In terms of profitability, IGAP's ROE is +3.93%, compared to STXS's ROE of -2.17%. Regarding short-term risk, IGAP is less volatile compared to STXS. This indicates potentially lower risk in terms of short-term price fluctuations for IGAP.
IGAP vs UTMD Comparison
IGAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IGAP stands at 50.2M. In comparison, UTMD has a market cap of 182.2M. Regarding current trading prices, IGAP is priced at $3.24, while UTMD trades at $56.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IGAP currently has a P/E ratio of -10.52, whereas UTMD's P/E ratio is 14.80. In terms of profitability, IGAP's ROE is +3.93%, compared to UTMD's ROE of +0.11%. Regarding short-term risk, IGAP is more volatile compared to UTMD. This indicates potentially higher risk in terms of short-term price fluctuations for IGAP.
IGAP vs EKSO Comparison
IGAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IGAP stands at 50.2M. In comparison, EKSO has a market cap of 156.3M. Regarding current trading prices, IGAP is priced at $3.24, while EKSO trades at $4.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IGAP currently has a P/E ratio of -10.52, whereas EKSO's P/E ratio is -0.62. In terms of profitability, IGAP's ROE is +3.93%, compared to EKSO's ROE of -0.82%. Regarding short-term risk, IGAP is less volatile compared to EKSO. This indicates potentially lower risk in terms of short-term price fluctuations for IGAP.
IGAP vs ZTEK Comparison
IGAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IGAP stands at 50.2M. In comparison, ZTEK has a market cap of 155.4M. Regarding current trading prices, IGAP is priced at $3.24, while ZTEK trades at $1.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IGAP currently has a P/E ratio of -10.52, whereas ZTEK's P/E ratio is -18.62. In terms of profitability, IGAP's ROE is +3.93%, compared to ZTEK's ROE of -0.58%. Regarding short-term risk, IGAP is less volatile compared to ZTEK. This indicates potentially lower risk in terms of short-term price fluctuations for IGAP.
IGAP vs PDEX Comparison
IGAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IGAP stands at 50.2M. In comparison, PDEX has a market cap of 139.5M. Regarding current trading prices, IGAP is priced at $3.24, while PDEX trades at $42.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IGAP currently has a P/E ratio of -10.52, whereas PDEX's P/E ratio is 15.50. In terms of profitability, IGAP's ROE is +3.93%, compared to PDEX's ROE of +0.29%. Regarding short-term risk, IGAP is less volatile compared to PDEX. This indicates potentially lower risk in terms of short-term price fluctuations for IGAP.
IGAP vs KRMD Comparison
IGAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IGAP stands at 50.2M. In comparison, KRMD has a market cap of 131M. Regarding current trading prices, IGAP is priced at $3.24, while KRMD trades at $2.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IGAP currently has a P/E ratio of -10.52, whereas KRMD's P/E ratio is -23.67. In terms of profitability, IGAP's ROE is +3.93%, compared to KRMD's ROE of -0.30%. Regarding short-term risk, IGAP is less volatile compared to KRMD. This indicates potentially lower risk in terms of short-term price fluctuations for IGAP.
IGAP vs INFU Comparison
IGAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IGAP stands at 50.2M. In comparison, INFU has a market cap of 127.5M. Regarding current trading prices, IGAP is priced at $3.24, while INFU trades at $6.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IGAP currently has a P/E ratio of -10.52, whereas INFU's P/E ratio is 40.53. In terms of profitability, IGAP's ROE is +3.93%, compared to INFU's ROE of +0.08%. Regarding short-term risk, IGAP is less volatile compared to INFU. This indicates potentially lower risk in terms of short-term price fluctuations for IGAP.
IGAP vs ZJYL Comparison
IGAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IGAP stands at 50.2M. In comparison, ZJYL has a market cap of 122.2M. Regarding current trading prices, IGAP is priced at $3.24, while ZJYL trades at $0.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IGAP currently has a P/E ratio of -10.52, whereas ZJYL's P/E ratio is 39.02. In terms of profitability, IGAP's ROE is +3.93%, compared to ZJYL's ROE of +0.13%. Regarding short-term risk, IGAP is less volatile compared to ZJYL. This indicates potentially lower risk in terms of short-term price fluctuations for IGAP.
IGAP vs MBOT Comparison
IGAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IGAP stands at 50.2M. In comparison, MBOT has a market cap of 99.3M. Regarding current trading prices, IGAP is priced at $3.24, while MBOT trades at $2.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IGAP currently has a P/E ratio of -10.52, whereas MBOT's P/E ratio is -4.27. In terms of profitability, IGAP's ROE is +3.93%, compared to MBOT's ROE of -0.85%. Regarding short-term risk, IGAP is less volatile compared to MBOT. This indicates potentially lower risk in terms of short-term price fluctuations for IGAP.
IGAP vs MLSS Comparison
IGAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IGAP stands at 50.2M. In comparison, MLSS has a market cap of 72.2M. Regarding current trading prices, IGAP is priced at $3.24, while MLSS trades at $0.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IGAP currently has a P/E ratio of -10.52, whereas MLSS's P/E ratio is -15.34. In terms of profitability, IGAP's ROE is +3.93%, compared to MLSS's ROE of -0.83%. Regarding short-term risk, IGAP is more volatile compared to MLSS. This indicates potentially higher risk in terms of short-term price fluctuations for IGAP.
IGAP vs AKYA Comparison
IGAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IGAP stands at 50.2M. In comparison, AKYA has a market cap of 56.9M. Regarding current trading prices, IGAP is priced at $3.24, while AKYA trades at $1.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IGAP currently has a P/E ratio of -10.52, whereas AKYA's P/E ratio is -1.19. In terms of profitability, IGAP's ROE is +3.93%, compared to AKYA's ROE of -5.06%. Regarding short-term risk, IGAP is less volatile compared to AKYA. This indicates potentially lower risk in terms of short-term price fluctuations for IGAP.
IGAP vs OMIC Comparison
IGAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IGAP stands at 50.2M. In comparison, OMIC has a market cap of 50.8M. Regarding current trading prices, IGAP is priced at $3.24, while OMIC trades at $20.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IGAP currently has a P/E ratio of -10.52, whereas OMIC's P/E ratio is -0.58. In terms of profitability, IGAP's ROE is +3.93%, compared to OMIC's ROE of -0.58%. Regarding short-term risk, IGAP is more volatile compared to OMIC. This indicates potentially higher risk in terms of short-term price fluctuations for IGAP.
IGAP vs DXR Comparison
IGAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IGAP stands at 50.2M. In comparison, DXR has a market cap of 41.7M. Regarding current trading prices, IGAP is priced at $3.24, while DXR trades at $8.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IGAP currently has a P/E ratio of -10.52, whereas DXR's P/E ratio is -95.89. In terms of profitability, IGAP's ROE is +3.93%, compared to DXR's ROE of +0.02%. Regarding short-term risk, IGAP is less volatile compared to DXR. This indicates potentially lower risk in terms of short-term price fluctuations for IGAP.
IGAP vs NEPH Comparison
IGAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IGAP stands at 50.2M. In comparison, NEPH has a market cap of 34.7M. Regarding current trading prices, IGAP is priced at $3.24, while NEPH trades at $3.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IGAP currently has a P/E ratio of -10.52, whereas NEPH's P/E ratio is 40.88. In terms of profitability, IGAP's ROE is +3.93%, compared to NEPH's ROE of +0.09%. Regarding short-term risk, IGAP is less volatile compared to NEPH. This indicates potentially lower risk in terms of short-term price fluctuations for IGAP.
IGAP vs POCI Comparison
IGAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IGAP stands at 50.2M. In comparison, POCI has a market cap of 34.1M. Regarding current trading prices, IGAP is priced at $3.24, while POCI trades at $4.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IGAP currently has a P/E ratio of -10.52, whereas POCI's P/E ratio is -4.89. In terms of profitability, IGAP's ROE is +3.93%, compared to POCI's ROE of -0.54%. Regarding short-term risk, IGAP is less volatile compared to POCI. This indicates potentially lower risk in terms of short-term price fluctuations for IGAP.
IGAP vs SDC Comparison
IGAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IGAP stands at 50.2M. In comparison, SDC has a market cap of 29.1M. Regarding current trading prices, IGAP is priced at $3.24, while SDC trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IGAP currently has a P/E ratio of -10.52, whereas SDC's P/E ratio is -0.03. In terms of profitability, IGAP's ROE is +3.93%, compared to SDC's ROE of -1.96%. Regarding short-term risk, IGAP is less volatile compared to SDC. This indicates potentially lower risk in terms of short-term price fluctuations for IGAP.
IGAP vs IVC Comparison
IGAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IGAP stands at 50.2M. In comparison, IVC has a market cap of 24.9M. Regarding current trading prices, IGAP is priced at $3.24, while IVC trades at $0.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IGAP currently has a P/E ratio of -10.52, whereas IVC's P/E ratio is -0.79. In terms of profitability, IGAP's ROE is +3.93%, compared to IVC's ROE of -0.46%. Regarding short-term risk, IGAP is less volatile compared to IVC. This indicates potentially lower risk in terms of short-term price fluctuations for IGAP.
IGAP vs FEMY Comparison
IGAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IGAP stands at 50.2M. In comparison, FEMY has a market cap of 21.8M. Regarding current trading prices, IGAP is priced at $3.24, while FEMY trades at $0.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IGAP currently has a P/E ratio of -10.52, whereas FEMY's P/E ratio is -0.88. In terms of profitability, IGAP's ROE is +3.93%, compared to FEMY's ROE of -3.92%. Regarding short-term risk, IGAP is less volatile compared to FEMY. This indicates potentially lower risk in terms of short-term price fluctuations for IGAP.
IGAP vs RVP Comparison
IGAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IGAP stands at 50.2M. In comparison, RVP has a market cap of 20.1M. Regarding current trading prices, IGAP is priced at $3.24, while RVP trades at $0.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IGAP currently has a P/E ratio of -10.52, whereas RVP's P/E ratio is -0.88. In terms of profitability, IGAP's ROE is +3.93%, compared to RVP's ROE of -0.27%. Regarding short-term risk, IGAP is less volatile compared to RVP. This indicates potentially lower risk in terms of short-term price fluctuations for IGAP.
IGAP vs NXGLW Comparison
IGAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IGAP stands at 50.2M. In comparison, NXGLW has a market cap of 19.2M. Regarding current trading prices, IGAP is priced at $3.24, while NXGLW trades at $0.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IGAP currently has a P/E ratio of -10.52, whereas NXGLW's P/E ratio is -0.20. In terms of profitability, IGAP's ROE is +3.93%, compared to NXGLW's ROE of -0.63%. Regarding short-term risk, IGAP is more volatile compared to NXGLW. This indicates potentially higher risk in terms of short-term price fluctuations for IGAP.
IGAP vs WOK Comparison
IGAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IGAP stands at 50.2M. In comparison, WOK has a market cap of 18.3M. Regarding current trading prices, IGAP is priced at $3.24, while WOK trades at $0.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IGAP currently has a P/E ratio of -10.52, whereas WOK's P/E ratio is -3.06. In terms of profitability, IGAP's ROE is +3.93%, compared to WOK's ROE of -0.30%. Regarding short-term risk, IGAP is less volatile compared to WOK. This indicates potentially lower risk in terms of short-term price fluctuations for IGAP.
IGAP vs HBIO Comparison
IGAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IGAP stands at 50.2M. In comparison, HBIO has a market cap of 18.3M. Regarding current trading prices, IGAP is priced at $3.24, while HBIO trades at $0.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IGAP currently has a P/E ratio of -10.52, whereas HBIO's P/E ratio is -0.32. In terms of profitability, IGAP's ROE is +3.93%, compared to HBIO's ROE of -1.10%. Regarding short-term risk, IGAP is less volatile compared to HBIO. This indicates potentially lower risk in terms of short-term price fluctuations for IGAP.
IGAP vs NXGL Comparison
IGAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IGAP stands at 50.2M. In comparison, NXGL has a market cap of 17.4M. Regarding current trading prices, IGAP is priced at $3.24, while NXGL trades at $2.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IGAP currently has a P/E ratio of -10.52, whereas NXGL's P/E ratio is -5.04. In terms of profitability, IGAP's ROE is +3.93%, compared to NXGL's ROE of -0.63%. Regarding short-term risk, IGAP is less volatile compared to NXGL. This indicates potentially lower risk in terms of short-term price fluctuations for IGAP.
IGAP vs MHUA Comparison
IGAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IGAP stands at 50.2M. In comparison, MHUA has a market cap of 15.8M. Regarding current trading prices, IGAP is priced at $3.24, while MHUA trades at $0.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IGAP currently has a P/E ratio of -10.52, whereas MHUA's P/E ratio is 1.25. In terms of profitability, IGAP's ROE is +3.93%, compared to MHUA's ROE of +0.09%. Regarding short-term risk, IGAP is less volatile compared to MHUA. This indicates potentially lower risk in terms of short-term price fluctuations for IGAP.
IGAP vs LUCYW Comparison
IGAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IGAP stands at 50.2M. In comparison, LUCYW has a market cap of 13.8M. Regarding current trading prices, IGAP is priced at $3.24, while LUCYW trades at $0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IGAP currently has a P/E ratio of -10.52, whereas LUCYW's P/E ratio is N/A. In terms of profitability, IGAP's ROE is +3.93%, compared to LUCYW's ROE of -0.95%. Regarding short-term risk, IGAP is less volatile compared to LUCYW. This indicates potentially lower risk in terms of short-term price fluctuations for IGAP.
IGAP vs LUCY Comparison
IGAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IGAP stands at 50.2M. In comparison, LUCY has a market cap of 9.5M. Regarding current trading prices, IGAP is priced at $3.24, while LUCY trades at $3.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IGAP currently has a P/E ratio of -10.52, whereas LUCY's P/E ratio is 0.07. In terms of profitability, IGAP's ROE is +3.93%, compared to LUCY's ROE of -0.95%. Regarding short-term risk, IGAP is less volatile compared to LUCY. This indicates potentially lower risk in terms of short-term price fluctuations for IGAP.
IGAP vs POAI Comparison
IGAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IGAP stands at 50.2M. In comparison, POAI has a market cap of 8.7M. Regarding current trading prices, IGAP is priced at $3.24, while POAI trades at $0.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IGAP currently has a P/E ratio of -10.52, whereas POAI's P/E ratio is -0.68. In terms of profitability, IGAP's ROE is +3.93%, compared to POAI's ROE of -5.91%. Regarding short-term risk, IGAP is less volatile compared to POAI. This indicates potentially lower risk in terms of short-term price fluctuations for IGAP.
IGAP vs NSTG Comparison
IGAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IGAP stands at 50.2M. In comparison, NSTG has a market cap of 5.1M. Regarding current trading prices, IGAP is priced at $3.24, while NSTG trades at $0.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IGAP currently has a P/E ratio of -10.52, whereas NSTG's P/E ratio is -0.03. In terms of profitability, IGAP's ROE is +3.93%, compared to NSTG's ROE of -1.43%. Regarding short-term risk, IGAP is less volatile compared to NSTG. This indicates potentially lower risk in terms of short-term price fluctuations for IGAP.
IGAP vs GCTK Comparison
IGAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IGAP stands at 50.2M. In comparison, GCTK has a market cap of 4.1M. Regarding current trading prices, IGAP is priced at $3.24, while GCTK trades at $0.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IGAP currently has a P/E ratio of -10.52, whereas GCTK's P/E ratio is N/A. In terms of profitability, IGAP's ROE is +3.93%, compared to GCTK's ROE of +3.93%. Regarding short-term risk, IGAP is less volatile compared to GCTK. This indicates potentially lower risk in terms of short-term price fluctuations for IGAP.
IGAP vs STSS Comparison
IGAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IGAP stands at 50.2M. In comparison, STSS has a market cap of 3.8M. Regarding current trading prices, IGAP is priced at $3.24, while STSS trades at $3.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IGAP currently has a P/E ratio of -10.52, whereas STSS's P/E ratio is N/A. In terms of profitability, IGAP's ROE is +3.93%, compared to STSS's ROE of -0.99%. Regarding short-term risk, IGAP is less volatile compared to STSS. This indicates potentially lower risk in terms of short-term price fluctuations for IGAP.
IGAP vs GMVD Comparison
IGAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IGAP stands at 50.2M. In comparison, GMVD has a market cap of 1.8M. Regarding current trading prices, IGAP is priced at $3.24, while GMVD trades at $0.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IGAP currently has a P/E ratio of -10.52, whereas GMVD's P/E ratio is -0.01. In terms of profitability, IGAP's ROE is +3.93%, compared to GMVD's ROE of +2.09%. Regarding short-term risk, IGAP is less volatile compared to GMVD. This indicates potentially lower risk in terms of short-term price fluctuations for IGAP.
IGAP vs GMVDW Comparison
IGAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IGAP stands at 50.2M. In comparison, GMVDW has a market cap of 1.8M. Regarding current trading prices, IGAP is priced at $3.24, while GMVDW trades at $7.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IGAP currently has a P/E ratio of -10.52, whereas GMVDW's P/E ratio is N/A. In terms of profitability, IGAP's ROE is +3.93%, compared to GMVDW's ROE of +2.09%. Regarding short-term risk, IGAP is less volatile compared to GMVDW. This indicates potentially lower risk in terms of short-term price fluctuations for IGAP.
IGAP vs AVGR Comparison
IGAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IGAP stands at 50.2M. In comparison, AVGR has a market cap of 1.5M. Regarding current trading prices, IGAP is priced at $3.24, while AVGR trades at $0.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IGAP currently has a P/E ratio of -10.52, whereas AVGR's P/E ratio is -0.05. In terms of profitability, IGAP's ROE is +3.93%, compared to AVGR's ROE of -54.25%. Regarding short-term risk, IGAP is less volatile compared to AVGR. This indicates potentially lower risk in terms of short-term price fluctuations for IGAP.
IGAP vs LMNX Comparison
IGAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IGAP stands at 50.2M. In comparison, LMNX has a market cap of 0. Regarding current trading prices, IGAP is priced at $3.24, while LMNX trades at $36.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IGAP currently has a P/E ratio of -10.52, whereas LMNX's P/E ratio is N/A. In terms of profitability, IGAP's ROE is +3.93%, compared to LMNX's ROE of +0.03%. Regarding short-term risk, IGAP is more volatile compared to LMNX. This indicates potentially higher risk in terms of short-term price fluctuations for IGAP.
IGAP vs APR Comparison
IGAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IGAP stands at 50.2M. In comparison, APR has a market cap of 0. Regarding current trading prices, IGAP is priced at $3.24, while APR trades at $37.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IGAP currently has a P/E ratio of -10.52, whereas APR's P/E ratio is 22.59. In terms of profitability, IGAP's ROE is +3.93%, compared to APR's ROE of +9.81%. Regarding short-term risk, IGAP is more volatile compared to APR. This indicates potentially higher risk in terms of short-term price fluctuations for IGAP.
IGAP vs IIN Comparison
IGAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IGAP stands at 50.2M. In comparison, IIN has a market cap of 0. Regarding current trading prices, IGAP is priced at $3.24, while IIN trades at $24.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IGAP currently has a P/E ratio of -10.52, whereas IIN's P/E ratio is 226.45. In terms of profitability, IGAP's ROE is +3.93%, compared to IIN's ROE of -0.00%. Regarding short-term risk, IGAP is more volatile compared to IIN. This indicates potentially higher risk in terms of short-term price fluctuations for IGAP.
IGAP vs ATRS Comparison
IGAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IGAP stands at 50.2M. In comparison, ATRS has a market cap of 0. Regarding current trading prices, IGAP is priced at $3.24, while ATRS trades at $5.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IGAP currently has a P/E ratio of -10.52, whereas ATRS's P/E ratio is 14.95. In terms of profitability, IGAP's ROE is +3.93%, compared to ATRS's ROE of +0.31%. Regarding short-term risk, IGAP is more volatile compared to ATRS. This indicates potentially higher risk in terms of short-term price fluctuations for IGAP.
IGAP vs HRC Comparison
IGAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IGAP stands at 50.2M. In comparison, HRC has a market cap of 0. Regarding current trading prices, IGAP is priced at $3.24, while HRC trades at $155.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IGAP currently has a P/E ratio of -10.52, whereas HRC's P/E ratio is 41.92. In terms of profitability, IGAP's ROE is +3.93%, compared to HRC's ROE of +0.14%. Regarding short-term risk, IGAP is more volatile compared to HRC. This indicates potentially higher risk in terms of short-term price fluctuations for IGAP.